GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (FRA:5HTA) » Definitions » Net Income Including Noncontrolling Interests

Harpoon Therapeutics (FRA:5HTA) Net Income Including Noncontrolling Interests : €-28.69 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Harpoon Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2023 was €-1.69 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 was €-28.69 Mil.

Harpoon Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Harpoon Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Net Income Including Noncontrolling Interests Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -24.06 -50.02 -41.02 -103.30 -63.94

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.76 -17.39 -10.59 0.98 -1.69

Harpoon Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harpoon Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (FRA:5HTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (FRA:5HTA) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
HEPA ACER VINC ICU CBIO PLUR ONCT IGXT AZTR ELEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HARP:USA
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.harpoontx.com
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Harpoon Therapeutics (FRA:5HTA) Headlines

No Headlines